Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Ribavirin
100%
Protease Inhibitors
100%
Dasabuvir
100%
Ombitasvir/paritaprevir/ritonavir
100%
Prospective multicenter Trial
100%
Hepatitis C Virus Genotypes
60%
SVR12
60%
Adverse Events
40%
First-generation Protease Inhibitors
40%
Sustained Virological Response
40%
Chronic Liver Disease
20%
Intention-to-treat
20%
Response Rate
20%
Patient-reported Outcomes
20%
Patient-initiated
20%
Hepatocellular Carcinoma
20%
Trial Registration
20%
Pneumonia
20%
Hepatitis C Virus Infection
20%
Antiviral Response
20%
Genotype 1
20%
Fibroscan
20%
Serious Adverse Events
20%
Multicenter Clinical Trial
20%
ALT Level
20%
Partial Responder
20%
Per-protocol
20%
Relapser
20%
Resistance-associated Variants
20%
Telaprevir
20%
Palpation
20%
Peginterferon
20%
Boceprevir
20%
Previous Treatment
20%
Ankle Fracture
20%
Genotype 1b
20%
Investigator-initiated
20%
Inhibitor Treatment
20%
Psychiatric Admission
20%
Peginterferon/ribavirin
20%
Pharmacology, Toxicology and Pharmaceutical Science
Ribavirin
100%
Ritonavir
100%
Proteinase Inhibitor
100%
Paritaprevir
100%
Ombitasvir
100%
Dasabuvir
100%
Adverse Event
50%
Hepatitis C Virus Genotype 1
50%
Peginterferon
33%
Clinical Trial
16%
Liver Cell Carcinoma
16%
Antivirus Agent
16%
Hepatitis C
16%
Chronic Liver Disease
16%
Weakness
16%
Boceprevir
16%
Telaprevir
16%
Heart Palpitation
16%
Ankle Fracture
16%
Side Effect
16%
Pneumonia
16%